X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (98) 98
male (69) 69
female (68) 68
middle aged (62) 62
adult (56) 56
infectious diseases (55) 55
index medicus (52) 52
immunology (43) 43
hiv infections - drug therapy (40) 40
hiv (35) 35
life sciences (27) 27
risk factors (27) 27
hiv infections - complications (26) 26
human-immunodeficiency-virus (24) 24
microbiology (22) 22
aids (20) 20
treatment outcome (20) 20
human immunodeficiency virus--hiv (19) 19
aged (18) 18
antiretroviral therapy (18) 18
hiv infection (18) 18
disease (16) 16
cd4 lymphocyte count (15) 15
health aspects (15) 15
viral load (15) 15
anti-hiv agents - therapeutic use (14) 14
drug therapy (14) 14
prospective studies (14) 14
antiretroviral drugs (13) 13
virology (13) 13
gastroenterology & hepatology (12) 12
human health and pathology (12) 12
patients (12) 12
virus diseases (12) 12
[sdv.mhep.mi]life sciences [q-bio]/human health and pathology/infectious diseases (11) 11
mortality (11) 11
antiviral agents - therapeutic use (10) 10
cirrhosis (10) 10
hepatitis c (10) 10
hepatitis c - complications (10) 10
highly active antiretroviral therapy (10) 10
hiv infections - immunology (10) 10
hiv-1 (10) 10
prognosis (10) 10
rheumatology (10) 10
aids/hiv (9) 9
antiretroviral therapy, highly active (9) 9
antiviral agents (9) 9
cohort studies (9) 9
hepatitis (9) 9
hiv infections - virology (9) 9
infected patients (9) 9
time factors (9) 9
care and treatment (8) 8
cohort (8) 8
france (8) 8
hiv patients (8) 8
infection (8) 8
infections (8) 8
liver (8) 8
liver transplantation (8) 8
research article (8) 8
young adult (8) 8
acquired immune deficiency syndrome--aids (7) 7
acquired immunodeficiency syndrome - complications (7) 7
active antiretroviral therapy (7) 7
anti-hiv agents - adverse effects (7) 7
disease progression (7) 7
drug therapy, combination (7) 7
follow-up studies (7) 7
hiv infections - epidemiology (7) 7
human immunodeficiency virus (7) 7
medicine, general & internal (7) 7
protease inhibitors (7) 7
rna, viral - blood (7) 7
survival (7) 7
[ sdv.imm ] life sciences [q-bio]/immunology (6) 6
[sdv.imm]life sciences [q-bio]/immunology (6) 6
[sdv.spee]life sciences [q-bio]/santé publique et épidémiologie (6) 6
abridged index medicus (6) 6
acquired immune deficiency syndrome (6) 6
anti-retroviral agents - therapeutic use (6) 6
antiretroviral therapy, highly active - adverse effects (6) 6
antiretroviral therapy, highly active - methods (6) 6
cd4 antigen (6) 6
chronic hepatitis-c (6) 6
comorbidity (6) 6
epidemiology (6) 6
france - epidemiology (6) 6
hepatitis c virus (6) 6
hepatitis c, chronic - drug therapy (6) 6
hiv infections (6) 6
hiv infections - mortality (6) 6
infectious disease (6) 6
internal medicine (6) 6
medicine (6) 6
pharmacology & pharmacy (6) 6
population (6) 6
public, environmental & occupational health (6) 6
raltegravir potassium (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2017, Volume 17, Issue 5, pp. 510 - 519
Summary Background Listeriosis is a severe foodborne infection and a notifiable disease in France. We did a nationwide prospective study to characterise its... 
Infectious Disease | MORTALITY | MENINGITIS | INFECTIOUS DISEASES | MONOCYTOGENES | RISK-FACTORS | MANAGEMENT | GUIDELINES | SURVEILLANCE | PREGNANCY | Foodborne Diseases - microbiology | Infant, Newborn, Diseases - epidemiology | Prognosis | Prospective Studies | Humans | Listeriosis - diagnosis | Bacteremia - mortality | Male | Infant, Newborn, Diseases - microbiology | Listeriosis - epidemiology | Mandatory Reporting | Listeria monocytogenes - classification | Adult | Female | Pregnancy Complications, Infectious - microbiology | Infant, Newborn | Meningoencephalitis - epidemiology | France - epidemiology | Meningoencephalitis - mortality | Pregnancy Complications, Infectious - epidemiology | Risk Factors | Listeria monocytogenes - isolation & purification | Hospitalization | Infectious Disease Transmission, Vertical | Pregnancy | Meningoencephalitis - microbiology | Bacteremia - epidemiology | Listeriosis - microbiology | Aged | Population Surveillance | Listeriosis | Neonates | Food-borne diseases | Disease | Brain stem | Clinical trials | Infections | Genomes | Gestation | Epidemiology | Risk factors | Windows (intervals) | Listeria | Meningitis | Public health | Food | Dexamethasone | Bacterial infections | Mortality | Fetuses | Regression analysis | Clustering | Patients | Bacteremia | Meningoencephalitis | Studies | Surveillance | Medical prognosis | Health risk assessment | Cancer | Life Sciences
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 369, Issue 9569, pp. 1261 - 1269
Summary Background Raltegravir (MK-0518) is an HIV-1 integrase inhibitor with potent in-vitro activity against HIV-1 strains including those resistant to... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | ANTIRETROVIRAL DRUGS | THERAPY | HIV-1-INFECTED INDIVIDUALS | INFECTION | DRUG-RESISTANCE | PREVALENCE | ENFUVIRTIDE | HIV-1 | Drug Resistance, Multiple | Humans | Middle Aged | Male | HIV Integrase Inhibitors - administration & dosage | Viral Load | Oligopeptides - therapeutic use | Dose-Response Relationship, Drug | Atazanavir Sulfate | Adult | Female | Raltegravir Potassium | Organic Chemicals - administration & dosage | Pyridines - therapeutic use | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Pyridines - pharmacology | Oligopeptides - pharmacology | Viral drug resistance | Care and treatment | Dosage and administration | Drug therapy | HIV infection | Raltegravir | Design | Studies | Antiretroviral drugs | Plasma | Inhibitor drugs | Protease inhibitors | Conferences | Human immunodeficiency virus--HIV | Mortality | Gene expression | Drug resistance | Patients | RNA-directed DNA polymerase | Laboratories | Toxicity | Viruses | Genomes | Randomization | Motivation | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Safety | Drug dosages | Integrase | Phenotypes | Effectiveness | Proteinase inhibitors | Ribonucleic acid--RNA | Antiretroviral therapy | CD4 antigen | Non-nucleoside reverse transcriptase inhibitors | Inhibitors | Nucleosides | Index Medicus | Abridged Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 12/2018, Volume 13, Issue 12, p. e0208657
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2019, Volume 14, Issue 1, p. e0211286
Journal Article
JAMA, ISSN 0098-7484, 09/2016, Volume 316, Issue 11, pp. 1172 - 1180
IMPORTANCE: One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing... 
AGENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER | ADALIMUMAB | ANTITUMOR-NECROSIS-FACTOR | INADEQUATE RESPONSE | RITUXIMAB | DOUBLE-BLIND | OUTCOMES | INHIBITOR | ABATACEPT | Care and treatment | Research | Tumor necrosis factor | Rheumatoid arthritis | Clinical trials | Tumor necrosis factor-TNF | TNF inhibitors
Journal Article